Ophthalmologica · 2018 · 27 citations · 34 references
MedicineOphthalmologyPharmacotherapyOcular DiseaseOphthalmic SurgeryPediatric OphthalmologyRetinal PharmacotherapyRetinal SurgeryRetinopathy Of PrematurityVitreoretinal SurgeryAnti-vegf Ocular TherapyIntravitreal Anti-vascular Endothelial Growth Factor TherapyPrematurity EffectsRetinopathy Of Prematurity PharmacotherapyRetinopathy Of Prematurity Surgery
<b><i>Purpose:</i></b> To investigate the effects of bevacizumab and ranibizumab in the treatment of type 1 retinopathy of prematurity (ROP) affecting zone 1. <b><i>Methods:</i></b> Files of the patients who received intravitreal bevacizumab (IVB) or ranibizumab (IVR) treatment for ROP affecting zone 1 were evaluated retrospectively. Spherical equivalent (SE) and axial length (AXL) measurements were performed at 1 year of adjusted age. <b><i>Results:</i></b> Sixty-eight eyes of 37 patients were included in the study. All patients had initial disease regression but 6 patients (4 in the IVB, 2 in the IVR group) showed reactivation (<i>p</i> = 0.679). The number of eyes with incomplete vascularization were 15 and 12 in the IVB and IVR groups, respectively (<i>p</i> = 0.725). Mean AXL was 20.50 ± 0.99 mm in the IVB group and 19.30 ± 0.48 mm in the IVR group (<i>p</i> &#x3c; 0.001). Mean SE was –1.49 ± 2.38 dpt in the IVB group and 0.98 ± 2.18 dpt in the IVR group (<i>p</i> &#x3c; 0.001). <b><i>Conclusion:</i></b> Bevacizumab and ranibizumab showed similar effectiveness in the treatment of type 1 ROP affecting zone 1. The AXL was longer and SE was more myopic in eyes treated with IVB. This difference might be caused by the longer intravitreal half-life of bevacizumab than ranibizumab.
34
Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration
Daniel Martín, Maureen G. Maguire, Stuart L. Fine et al. · Ophthalmology · 2012 · 1.7K citations · Full text
An international classification of retinopathy of prematurity
International Ophthalmology · 1985 · 1K citations
Medicine, Ophthalmology, Pediatrics +16